FDA
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Provides Clinical and Regulatory Update on Apraglutide
-
-
-
-
-
-
-
Ironwood Pharma (IRWD): Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with SBS-IF
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
-
-
-
-
-
-
-
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) and VectivBio (VECT) Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

